TY  - JOUR
AU  - Bernhardt, Alexander Maximilian
AU  - Rodríguez-Baz, Íñigo
AU  - Aldecoa, Iban
AU  - Arranz, Javier
AU  - Arriola-Infante, José Enrique
AU  - Maure-Blesa, Lucia
AU  - Carmona-Iragui, Maria
AU  - Longen, Sebastian
AU  - Trossbach, Svenja Verena
AU  - Giese, Armin
AU  - Matthias, Torsten
AU  - Benejam, Bessy
AU  - Videla, Laura
AU  - Del Hoyo Soriano, Laura
AU  - Barroeta, Isabel
AU  - Sanjuan, Aída
AU  - Fernández, Susana
AU  - Vaqué-Alcázar, Lídia
AU  - Rozalem Aranha, Mateus
AU  - Morcillo-Nieto, Alejandra O
AU  - Nübling, Georg
AU  - Wagemann, Olivia
AU  - Stockbauer, Anna
AU  - Tondo, Mireia
AU  - Bejanin, Alexandre
AU  - Lleó, Alberto
AU  - Alcolea, Daniel
AU  - Molina-Porcel, Laura
AU  - Fortea, Juan
AU  - Levin, Johannes
TI  - Alpha-synuclein co-pathology in Down syndrome-associated Alzheimer's disease.
JO  - Alzheimer's and dementia
VL  - 21
IS  - 6
SN  - 1552-5260
CY  - Hoboken, NJ
PB  - Wiley
M1  - DZNE-2025-00727
SP  - e70342
PY  - 2025
AB  - Alpha-synuclein (αSyn) seed amplification assay (SAA) enables in vivo study of αSyn but remains underexplored in Down syndrome-associated Alzheimer's disease (DSAD).We analyzed αSyn-SAA in cerebrospinal fluid (CSF) from 270 adults with Down syndrome, from the Down Alzheimer Barcelona Neuroimaging Initiative and from the AD21 cohort from the Department of Neurology at the University Hospital, Ludwig Maximilian University of Munich, Germany. Neuropathological examinations were conducted in 19 brain donors (five with ante mortem CSF). Participants were classified as asymptomatic or symptomatic (prodromal/dementia) Alzheimer's disease (AD). CSF Aβ1-42/1-40, CSF and plasma p-Tau181, and neurofilament light chain (NfL) levels were measured. Neuropathological evaluations assessed AD neuropathological changes and Lewy body pathology (LBP).ΑSyn-SAA was positive in 9.2
KW  - Humans
KW  - Alzheimer Disease: pathology
KW  - Alzheimer Disease: cerebrospinal fluid
KW  - alpha-Synuclein: cerebrospinal fluid
KW  - Down Syndrome: pathology
KW  - Down Syndrome: complications
KW  - Down Syndrome: cerebrospinal fluid
KW  - Female
KW  - Male
KW  - Middle Aged
KW  - Aged
KW  - Amyloid beta-Peptides: cerebrospinal fluid
KW  - Brain: pathology
KW  - Biomarkers: cerebrospinal fluid
KW  - tau Proteins: cerebrospinal fluid
KW  - tau Proteins: blood
KW  - Adult
KW  - Neurofilament Proteins: cerebrospinal fluid
KW  - Neurofilament Proteins: blood
KW  - Alzheimer's disease (Other)
KW  - Down syndrome (Other)
KW  - Lewy body pathology (Other)
KW  - biomarker (Other)
KW  - neuropathology (Other)
KW  - seed amplification assay (Other)
KW  - α‐synuclein (Other)
KW  - alpha-Synuclein (NLM Chemicals)
KW  - Amyloid beta-Peptides (NLM Chemicals)
KW  - Biomarkers (NLM Chemicals)
KW  - tau Proteins (NLM Chemicals)
KW  - Neurofilament Proteins (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:40528443
C2  - pmc:PMC12173960
DO  - DOI:10.1002/alz.70342
UR  - https://pub.dzne.de/record/279350
ER  -